AUS
NZ
UK
CA
USA
IND
Citigroup Global Markets Australia Pty Limited has informed the ASX that trading in a CitiFirst MINI Long warrant linked to 4DMedical Ltd (ASX:4DX) has been suspended following the activation of a Stop Loss Level Event. The warrant, listed under the ASX Code 4DXKOE, was halted on 2 July 2026 after the underlying parcel price fell to or below the Stop Loss Trigger Level of $3.9100. Investors holding the suspended MINI have a limited timeframe to sell back to Citigroup at the Stop Loss Amount or will receive an automatic cash settlement within 10 Business days. This incident underscores the leverage risk inherent in structured MINI products when the underlying asset price moves sharply against the position.<\/p> <\/div>
Key Points<\/h3>
- Issuer: Citigroup Global Markets Australia Pty Limited; underlying security: 4DMedical Ltd (ASX:4DX); product ticker: CTW<\/li>
- Event: Suspension of CitiFirst MINI Long warrant (ASX code: 4DXKOE) following Stop Loss Trigger Event on 2 July 2026<\/li>
- Stop Loss Trigger Level: $3.9100 per underlying parcel; Strike Price<\/a> or Final Instalment: $3.1254; Conversion Ratio: 1<\/li>
- Holders have until the Stop Loss Trading Close (4pm on the trading day after the day following the event) to sell back to Citigroup at the Stop Loss Amount; otherwise, automatic payment will occur within 10 business days<\/li>
- Investors should monitor the cash settlement, any further suspension or termination announcements, and price movements of 4DMedical Ltd shares<\/li>
<\/ul>
<\/div>
Details Behind the Suspension of 4DXKOE Due to Stop Loss Trigger Event<\/h2>
The CitiFirst MINI series terms specify that a Stop Loss Trigger Event occurs when the underlying parcel price trades at or below the designated Stop Loss Trigger Level for a MINI Long product. For the 4DXKOE series, this threshold was $3.9100 per underlying parcel. According to the update released on 2 July 2026, this level was breached during the trading session, leading Citigroup Global Markets Australia to immediately suspend the warrant from trading on the ASX.<\/p>
The Stop Loss Trigger Event mechanism is designed to limit losses for both issuer and holder. Once triggered, normal trading of the MINI Long product ceases. Suspension initiates a structured wind-down process culminating in termination of the series. Citigroup confirmed the suspension of 4DXKOE following this event, with the underlying security being 4DMedical Ltd, an ASX-listed medical technology firm.<\/p>
Financial Terms of the Suspended 4DXKOE MINI Long: Strike Price, Conversion Ratio, and Stop Loss Level<\/h2>
The company update details the financial parameters of the 4DXKOE series. The Strike Price, also known as the Final Instalment, was $3.1254. The Conversion Ratio was 1, indicating each MINI warrant corresponds to one underlying parcel—here, shares in 4DMedical Ltd. The Stop Loss Trigger Level, which triggered the suspension, was set at $3.9100 per parcel.<\/p>
These figures are crucial to understanding the product's economics at suspension. Since the Stop Loss Level ($3.9100) is above the Strike Price ($3.1254), the product included a buffer between financing cost and the point where Citigroup would intervene to limit losses. When 4DMedical's share price hit or dropped below $3.9100, this buffer was depleted, triggering the Stop Loss Event. The difference between Stop Loss Level and Strike Price represents the theoretical residual value—known as the Cash Amount or Stop Loss Amount—that holders may receive, though the precise Stop Loss Amount was not separately disclosed.<\/p>
Two-Day Window for 4DXKOE Holders to Sell Back to Citigroup<\/h2>
After suspension, Citigroup outlined a process allowing holders to exit their positions. From 2pm on the trading day immediately after the Stop Loss Trigger Event, Citigroup will post a bid on the ASX at the Cash Amount level, as defined in the Terms of Issue. This bid remains open until 4pm on the following trading day, known as the Stop Loss Trading Close.<\/p>
During this limited trading window, holders can sell their CitiFirst MINI back to Citigroup at the Stop Loss Amount, offering flexibility to close positions actively. Those who do not sell within this timeframe will receive the Stop Loss Amount via an automatic cash payment within 10 business days after the trading day following the event, at which point the MINI will expire.<\/p>
Automatic Cash Settlement for Holders Not Selling Before Stop Loss Trading Close<\/h2>
Holders who choose not to sell their 4DXKOE warrants during the trading window will receive the Stop Loss Amount automatically. Citigroup confirmed payments will be made within 10 business days following the trading day after the Stop Loss Trigger Event. Upon payment, the CitiFirst MINI will expire.<\/p>
This automatic settlement requires no action from holders but forfeits the opportunity to trade during the brief window. The 10-business-day period allows Citigroup to calculate and distribute residual cash values to all affected holders. The total aggregate payment amount was not disclosed.<\/p>
Implications of 4DMedical Share Price Movement for the Underlying Security<\/h2>
The Stop Loss Event indicates that 4DMedical's share price traded at or below $3.9100 during the trading session on 2 July 2026. This outcome reflects the structured product's terms and the underlying security's price action at that time. The company update does not comment on reasons behind the share price movement or provide forward-looking statements about 4DMedical's business or prospects.<\/p>
Direct investors in 4DMedical Ltd should understand that the suspension and termination of this leveraged structured product do not directly impact the company's fundamentals, operations, or primary listing. The Stop Loss Event results from the product's design and issuer risk management, not from any corporate announcement or development by 4DMedical. The immediate share price effect on 4DMedical was not clarified in the update.<\/p>
Citigroup’s Role as Issuer and Market Maker for CitiFirst MINI Series<\/h2>
Citigroup Global Markets Australia Pty Limited issues the CitiFirst product range, including MINIs, Structured Finance Instruments (SFIs), Trading Warrants, Turbos, and Instalments. Operating under Australian Business Number 64 003 114 832 and Australian Financial Services Licence 240992, Citigroup participates in both the ASX Group and Cboe Australia, accessing multiple domestic exchanges.<\/p>
As issuer and market maker for CitiFirst MINIs, Citigroup is contractually obliged to post a bid at the Cash Amount during the Stop Loss trading window. This obligation is stipulated in the Terms of Issue and ensures holders have a liquidity option after normal trading suspension. This dual role is standard for exchange-traded structured products in Australia.<\/p>
Functionality of CitiFirst MINI Long Products and Purpose of Stop Loss Levels<\/h2>
CitiFirst MINI Long products are leveraged instruments that provide exposure to an underlying security by requiring only a fraction of the full market price upfront, with Citigroup financing the remainder up to the Strike Price. This leverage magnifies potential gains and losses relative to the capital invested. To manage risk, the issuer sets a Stop Loss Trigger Level above the Strike Price.<\/p>
The Stop Loss Level acts as an automatic safeguard. If the underlying price falls to or below this level, the product is suspended and wound down before losses can erode the Strike Price, protecting holders from owing money and the issuer from unhedged credit risk. The 4DXKOE series followed this design, with a Stop Loss Level at $3.9100, providing a margin above the Strike Price of $3.1254.<\/p>
Contact Information for Holders of 4DXKOE<\/h2>
Citigroup advises holders of the affected 4DXKOE series to contact their financial adviser or the CitiFirst helpline at 1300 30 70 70 for further information. Given the limited Stop Loss trading window—from 2pm on the trading day after the event until 4pm the following trading day—holders wishing to sell should act quickly and seek professional guidance.<\/p>
Holders uncertain about their options or tax implications of the Stop Loss Amount payment should consult qualified financial or tax advisers. The Terms of Issue provide the definitive contractual framework governing settlement, with the company update referencing these terms as the authoritative source for definitions of Cash Amount and Stop Loss Amount. Any discrepancies should be resolved by referring to the formal Terms of Issue.<\/p>
Considerations for Investors in Other CitiFirst MINI Products Linked to Volatile Stocks<\/h2>
The 4DXKOE suspension illustrates the stop-loss mechanism embedded in all CitiFirst MINI Long and MINI Short products. Investors holding other CitiFirst MINIs linked to smaller or volatile ASX-listed securities should review their Stop Loss Trigger Levels relative to current market prices. The closer an underlying security’s price is to its MINI’s Stop Loss Level, the higher the chance of a similar suspension.<\/p>
Market participants and structured product investors should consider this event within the context of broader market conditions and the volatility of small-cap stocks. While this update pertains specifically to 4DXKOE and 4DMedical Ltd, the same risk management framework applies across the CitiFirst MINI range. Investors are advised to consult relevant product disclosure statements and terms of issue, and to monitor underlying security prices against Stop Loss Levels continuously.<\/p>
Details Behind the Suspension of 4DXKOE Due to Stop Loss Trigger Event<\/h2>
The CitiFirst MINI series terms specify that a Stop Loss Trigger Event occurs when the underlying parcel price trades at or below the designated Stop Loss Trigger Level for a MINI Long product. For the 4DXKOE series, this threshold was $3.9100 per underlying parcel. According to the update released on 2 July 2026, this level was breached during the trading session, leading Citigroup Global Markets Australia to immediately suspend the warrant from trading on the ASX.<\/p>
The Stop Loss Trigger Event mechanism is designed to limit losses for both issuer and holder. Once triggered, normal trading of the MINI Long product ceases. Suspension initiates a structured wind-down process culminating in termination of the series. Citigroup confirmed the suspension of 4DXKOE following this event, with the underlying security being 4DMedical Ltd, an ASX-listed medical technology firm.<\/p>
Financial Terms of the Suspended 4DXKOE MINI Long: Strike Price, Conversion Ratio, and Stop Loss Level<\/h2>
The company update details the financial parameters of the 4DXKOE series. The Strike Price, also known as the Final Instalment, was $3.1254. The Conversion Ratio was 1, indicating each MINI warrant corresponds to one underlying parcel—here, shares in 4DMedical Ltd. The Stop Loss Trigger Level, which triggered the suspension, was set at $3.9100 per parcel.<\/p>
These figures are crucial to understanding the product's economics at suspension. Since the Stop Loss Level ($3.9100) is above the Strike Price ($3.1254), the product included a buffer between financing cost and the point where Citigroup would intervene to limit losses. When 4DMedical's share price hit or dropped below $3.9100, this buffer was depleted, triggering the Stop Loss Event. The difference between Stop Loss Level and Strike Price represents the theoretical residual value—known as the Cash Amount or Stop Loss Amount—that holders may receive, though the precise Stop Loss Amount was not separately disclosed.<\/p>
Two-Day Window for 4DXKOE Holders to Sell Back to Citigroup<\/h2>
After suspension, Citigroup outlined a process allowing holders to exit their positions. From 2pm on the trading day immediately after the Stop Loss Trigger Event, Citigroup will post a bid on the ASX at the Cash Amount level, as defined in the Terms of Issue. This bid remains open until 4pm on the following trading day, known as the Stop Loss Trading Close.<\/p>
During this limited trading window, holders can sell their CitiFirst MINI back to Citigroup at the Stop Loss Amount, offering flexibility to close positions actively. Those who do not sell within this timeframe will receive the Stop Loss Amount via an automatic cash payment within 10 business days after the trading day following the event, at which point the MINI will expire.<\/p>
Automatic Cash Settlement for Holders Not Selling Before Stop Loss Trading Close<\/h2>
Holders who choose not to sell their 4DXKOE warrants during the trading window will receive the Stop Loss Amount automatically. Citigroup confirmed payments will be made within 10 business days following the trading day after the Stop Loss Trigger Event. Upon payment, the CitiFirst MINI will expire.<\/p>
This automatic settlement requires no action from holders but forfeits the opportunity to trade during the brief window. The 10-business-day period allows Citigroup to calculate and distribute residual cash values to all affected holders. The total aggregate payment amount was not disclosed.<\/p>
Implications of 4DMedical Share Price Movement for the Underlying Security<\/h2>
The Stop Loss Event indicates that 4DMedical's share price traded at or below $3.9100 during the trading session on 2 July 2026. This outcome reflects the structured product's terms and the underlying security's price action at that time. The company update does not comment on reasons behind the share price movement or provide forward-looking statements about 4DMedical's business or prospects.<\/p>
Direct investors in 4DMedical Ltd should understand that the suspension and termination of this leveraged structured product do not directly impact the company's fundamentals, operations, or primary listing. The Stop Loss Event results from the product's design and issuer risk management, not from any corporate announcement or development by 4DMedical. The immediate share price effect on 4DMedical was not clarified in the update.<\/p>
Citigroup’s Role as Issuer and Market Maker for CitiFirst MINI Series<\/h2>
Citigroup Global Markets Australia Pty Limited issues the CitiFirst product range, including MINIs, Structured Finance Instruments (SFIs), Trading Warrants, Turbos, and Instalments. Operating under Australian Business Number 64 003 114 832 and Australian Financial Services Licence 240992, Citigroup participates in both the ASX Group and Cboe Australia, accessing multiple domestic exchanges.<\/p>
As issuer and market maker for CitiFirst MINIs, Citigroup is contractually obliged to post a bid at the Cash Amount during the Stop Loss trading window. This obligation is stipulated in the Terms of Issue and ensures holders have a liquidity option after normal trading suspension. This dual role is standard for exchange-traded structured products in Australia.<\/p>
Functionality of CitiFirst MINI Long Products and Purpose of Stop Loss Levels<\/h2>
CitiFirst MINI Long products are leveraged instruments that provide exposure to an underlying security by requiring only a fraction of the full market price upfront, with Citigroup financing the remainder up to the Strike Price. This leverage magnifies potential gains and losses relative to the capital invested. To manage risk, the issuer sets a Stop Loss Trigger Level above the Strike Price.<\/p>
The Stop Loss Level acts as an automatic safeguard. If the underlying price falls to or below this level, the product is suspended and wound down before losses can erode the Strike Price, protecting holders from owing money and the issuer from unhedged credit risk. The 4DXKOE series followed this design, with a Stop Loss Level at $3.9100, providing a margin above the Strike Price of $3.1254.<\/p>
Contact Information for Holders of 4DXKOE<\/h2>
Citigroup advises holders of the affected 4DXKOE series to contact their financial adviser or the CitiFirst helpline at 1300 30 70 70 for further information. Given the limited Stop Loss trading window—from 2pm on the trading day after the event until 4pm the following trading day—holders wishing to sell should act quickly and seek professional guidance.<\/p>
Holders uncertain about their options or tax implications of the Stop Loss Amount payment should consult qualified financial or tax advisers. The Terms of Issue provide the definitive contractual framework governing settlement, with the company update referencing these terms as the authoritative source for definitions of Cash Amount and Stop Loss Amount. Any discrepancies should be resolved by referring to the formal Terms of Issue.<\/p>
Considerations for Investors in Other CitiFirst MINI Products Linked to Volatile Stocks<\/h2>
The 4DXKOE suspension illustrates the stop-loss mechanism embedded in all CitiFirst MINI Long and MINI Short products. Investors holding other CitiFirst MINIs linked to smaller or volatile ASX-listed securities should review their Stop Loss Trigger Levels relative to current market prices. The closer an underlying security’s price is to its MINI’s Stop Loss Level, the higher the chance of a similar suspension.<\/p>
Market participants and structured product investors should consider this event within the context of broader market conditions and the volatility of small-cap stocks. While this update pertains specifically to 4DXKOE and 4DMedical Ltd, the same risk management framework applies across the CitiFirst MINI range. Investors are advised to consult relevant product disclosure statements and terms of issue, and to monitor underlying security prices against Stop Loss Levels continuously.<\/p>
